The discovery of targeted bacteria capable of rescuing antibiotic-associated dysbiosis made it feasible to promote anti-tumor efficacy by modulating microbiome diversity, especially for HER2-positive BC patients. The gene discussed is ERBB2; the disease is neoplasm.